Concepedia

Author

Nader Pourhassan

Oregon Health & Science UniversityORCID

Also Known As

Nader Pourhassan, Nader Z Pourhassan, Nader Z. Pourhassan

15

Publications

495

Citations

10

H-Index

14

Concepts

All Affiliations

Oregon Health & Science UniversityCornell UniversityOregon National Primate Research CenterQuest Clinical Research (United States)Weill Cornell Medicine
NP

About

Nader Pourhassan is an author at Oregon Health & Science University specializing in humoral immunity, immunotherapy, and immune system.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

21

2

Cell Biology

1

1

21

3

Immunology

1

1

21

4

Humoral Immunity

1

1

21

5

Immune Surveillance

1

1

21

Nader Pourhassan

×

10

Publications

425

Citations

10

H-Index

YearCitations

CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14

Bruce K. Patterson, Harish Seethamraju, Kush Dhody,

International Journal of Infectious Diseases

2020

146

Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19

Bruce K. Patterson, Harish Seethamraju, Kush Dhody,

2020

103

PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection

Kush Dhody, Nader Pourhassan, Kazem Kazempour,

HIV Clinical Trials

2018

49

Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome

Norman Gaylis, Angela Ritter, Scott A. Kelly,

Clinical Infectious Diseases

2022

26

CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab

Xiao Chang, Helen L. Wu, Gabriela M. Webb,

Frontiers in Immunology

2021

25

Disruption of the CCL5/RANTES-CCR5 Pathway Restores Immune Homeostasis and Reduces Plasma Viral Load in Critical COVID-19

Bruce Pattterson, Harish Seetthamraju, Kush Dhody,

Research Square (Research Square)

2020

21

Antibody-based CCR5 blockade protects Macaques from mucosal SHIV transmission

Xiao Chang, Gabriela M. Webb, Helen L. Wu,

Nature Communications

2021

19

Suppression of human and simian immunodeficiency virus replication with the CCR5-specific antibody Leronlimab in two species

Xiao Chang, Jason S. Reed, Gabriela M. Webb,

PLoS Pathogens

2022

15

Safety, efficacy, and clinical outcomes of the anti-CCR5 inhibitor (Leronlimab): A pooled analysis of three clinical trials in patients with mTNBC.

Daniel L. Adams, Ashvathi Raghavakaimal, Cha‐Mei Tang,

Journal of Clinical Oncology

2022

11

Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab

Sohier Elneil, Jacob Lalezari, Nader Pourhassan

Journal of Translational Autoimmunity

2021

10

Page 1